Does Kaiser Permanente Cover Wegovy? The Answer Depends on Your Specific Plan Type and State

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Kaiser coverage for Wegovy depends on whether you have employer-sponsored, marketplace, Medicare Advantage, or Medicaid plans, with employer plans offering the widest coverage in 2026
• Most Kaiser employer plans now cover Wegovy with prior authorization requiring BMI 30+ (or 27+ with comorbidity) and documented lifestyle intervention, but impose quantity limits and step therapy
• Kaiser Medicare Advantage plans do NOT cover Wegovy for weight loss due to federal Medicare Part D exclusion of weight-loss drugs, though they cover Ozempic for diabetes
• Out-of-pocket costs range from $25-$100 copay for covered plans to $1,349 list price without coverage, making compounded semaglutide ($297-$375/month) the primary alternative for excluded members

Direct answer (40-60 words)

Kaiser Permanente's Wegovy coverage varies by plan type and state. Most employer-sponsored Kaiser plans cover Wegovy with prior authorization and medical necessity criteria as of 2026. Kaiser Medicare Advantage plans do not cover Wegovy for weight loss due to federal law. Kaiser Medicaid coverage depends on state Medicaid policy. Copays range from $25 to $100 when covered.

Table of contents

1. The coverage matrix: which Kaiser plan types cover Wegovy
2. Prior authorization requirements: what Kaiser requires for approval
3. The Medicare Advantage gap: why Kaiser seniors can't get Wegovy covered
4. State-by-state Medicaid variation in Kaiser regions
5. What most articles get wrong about Kaiser formulary tiers
6. Step therapy and quantity limits: the hidden coverage restrictions
7. Out-of-pocket costs by plan type
8. The appeal process when Kaiser denies coverage
9. Compounded semaglutide as the alternative pathway
10. How employer plan design overrides Kaiser's base formulary
11. The 2026 policy shift: what changed from 2024-2025
12. FAQ
13. Sources

The coverage matrix: which Kaiser plan types cover Wegovy

Kaiser Permanente operates as both an insurer and a healthcare provider, which means coverage decisions flow through both Kaiser's formulary committee and the specific benefit design of your plan. The answer to "does Kaiser cover Wegovy" requires knowing which of four plan categories you fall into.

Plan type	Wegovy coverage 2026	Prior auth required	Typical copay	Notes
Employer-sponsored (large group, 50+ employees)	Yes, most plans	Yes	$25-$60	Depends on employer's pharmacy benefit design
Employer-sponsored (small group, under 50)	Variable	Yes	$40-$100	About 60% of small group plans exclude weight-loss drugs
Individual/family marketplace (ACA)	Variable by state	Yes	$50-$100	8 of 9 Kaiser states now require coverage under state mandates
Medicare Advantage	No	N/A	Not covered	Federal Part D excludes weight-loss drugs
Medicaid (Kaiser managed)	Depends on state	Yes	$0-$3	Only in states with Medicaid obesity drug coverage

The most important distinction is between employer plans and government plans. Employer plans have discretion to cover Wegovy. Medicare Advantage plans are federally prohibited from covering weight-loss medications under Medicare Part D rules, even though Kaiser would otherwise include it.

Prior authorization requirements: what Kaiser requires for approval

When your Kaiser plan does cover Wegovy, approval is not automatic. Kaiser's prior authorization criteria as of 2026 follow the clinical trial inclusion criteria from the STEP program trials but add utilization management layers.

The standard prior authorization requires documentation of:

1. BMI threshold. BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

1. Documented lifestyle intervention. At least 90 days of a structured weight-loss program within the past 12 months. Kaiser accepts its own Healthy Weight for Life program, commercial programs like Weight Watchers, or provider-supervised diet and exercise plans with documented visits. The key is documentation. A note saying "patient reports trying diet and exercise" does not meet the standard. Kaiser wants visit dates, weight logs, and program enrollment records.

1. Exclusion of contraindications. No personal or family history of medullary thyroid carcinoma, no MEN 2 syndrome, no history of pancreatitis, no severe gastroparesis. Pregnancy and breastfeeding are absolute contraindications.

1. Prescriber requirements. The prescription must come from a Kaiser provider or, for out-of-network employer plans, a provider with documented obesity medicine credentials. Kaiser does not accept prior authorizations from telehealth-only platforms for Wegovy.

1. Step therapy in some plans. About 40% of Kaiser employer plans require a trial of a generic GLP-1 (typically liraglutide/Saxenda) before approving Wegovy. This adds 3 to 6 months to the approval timeline.

The prior authorization is valid for 12 months. Renewal requires documentation of at least 5% weight loss from baseline. If weight loss is under 5% at 6 months, Kaiser typically denies continued coverage unless there are documented improvements in comorbid conditions (A1C reduction, blood pressure improvement, etc.).

Processing time averages 3 to 7 business days for standard prior authorizations, 24 hours for urgent requests (defined as situations where delay would cause serious health deterioration, which is rare for weight-loss medications).

The Medicare Advantage gap: why Kaiser seniors can't get Wegovy covered

This is the single most common source of confusion. Kaiser Permanente offers Medicare Advantage plans in all nine of its operating regions. These plans are popular with seniors because they bundle medical and prescription coverage. But Medicare Advantage plans cannot cover Wegovy for weight loss, even though Kaiser's commercial plans do.

The reason is federal law. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes "agents used for weight loss or weight gain" from Medicare Part D coverage. This exclusion applies to all Part D plans, including Medicare Advantage plans with integrated Part D coverage.

Wegovy's FDA approval is specifically for chronic weight management. Even though the same drug (semaglutide) is covered under Medicare when prescribed as Ozempic for type 2 diabetes, Wegovy's weight-loss indication makes it a excluded drug under Part D rules.

Kaiser's Medicare Advantage formularies as of 2026 list Wegovy with the notation "Not covered, excluded Part D drug." There is no appeal pathway that changes this. The exclusion is statutory, not a Kaiser policy decision.

The practical consequence: Kaiser Medicare Advantage members who want semaglutide for weight loss have three options:

1. Get it prescribed as Ozempic for an on-label diabetes indication (requires actual type 2 diabetes diagnosis and A1C documentation)
2. Pay cash for brand-name Wegovy ($1,349 per month list price, though GoodRx and manufacturer coupons can reduce this)
3. Use compounded semaglutide from a 503B outsourcing facility, which is not covered by Medicare but costs $297 to $375 per month out of pocket

There is pending federal legislation (the Treat and Reduce Obesity Act, reintroduced in 2025) that would eliminate the Part D weight-loss drug exclusion, but as of April 2026 it has not passed. If it does pass, Kaiser Medicare Advantage plans would be required to cover Wegovy under the same prior authorization criteria as commercial plans.

State-by-state Medicaid variation in Kaiser regions

Kaiser Permanente manages Medicaid plans in seven states: California, Colorado, Hawaii, Oregon, Washington, Maryland, and Virginia (the District of Columbia also has a small Kaiser Medicaid presence). Wegovy coverage in these plans depends entirely on each state's Medicaid formulary policy.

State	Kaiser Medicaid Wegovy coverage 2026	Notes
California (Medi-Cal)	No	California Medicaid excludes Wegovy; covers Saxenda with prior auth
Colorado (Health First Colorado)	Yes, with restrictions	Requires BMI 30+, prior auth, 6-month lifestyle program
Hawaii (Med-QUEST)	No	Does not cover GLP-1s for weight loss
Oregon (OHP)	Yes	Covers Wegovy under obesity treatment benefit, prior auth required
Washington (Apple Health)	Yes	Added January 2026 under state mandate
Maryland (HealthChoice)	No	Excludes weight-loss medications
Virginia (Medallion 4.0)	No	Excludes weight-loss medications

The pattern: states with explicit obesity-as-disease Medicaid mandates (Colorado, Oregon, Washington) cover Wegovy. States without those mandates generally do not, because Medicaid programs face budget pressure and weight-loss drugs are expensive.

If you have Kaiser Medicaid coverage in a state that does not cover Wegovy, the same three alternatives apply: qualify for a diabetes indication, pay cash, or use compounded semaglutide.

What most articles get wrong about Kaiser formulary tiers

Most insurance explainer articles describe formulary tiers as a simple ladder: Tier 1 generics are cheapest, Tier 2 preferred brands cost more, Tier 3 non-preferred brands cost the most. This model does not explain how Kaiser handles Wegovy.

Kaiser uses a five-tier formulary structure in most regions, but Wegovy's placement varies by plan:

• Tier 1: Generic drugs ($5-$10 copay)
• Tier 2: Preferred brand drugs ($25-$40 copay)
• Tier 3: Non-preferred brand drugs ($50-$75 copay)
• Tier 4: Specialty drugs ($100-$150 copay or 20-30% coinsurance)
• Tier 5: Specialty tier with prior authorization and utilization management

Wegovy is listed as a Tier 4 or Tier 5 drug depending on the specific Kaiser plan. But here is what most articles miss: tier placement does not determine coverage. A drug can be listed in Tier 4 and still be excluded from your specific benefit design.

The correct question is not "what tier is Wegovy on Kaiser's formulary" but "does my specific Kaiser plan's benefit design include coverage for Tier 4/5 weight-loss medications?" Many small-group employer plans and all Medicare Advantage plans exclude coverage for certain drug classes regardless of tier placement.

You can verify this by logging into Kaiser's member portal, navigating to "Coverage and Costs," selecting "Prescription Drug List," and searching for Wegovy. If the result says "Not covered" or "Excluded," your plan does not cover it even if it appears on the formulary. If it says "Covered, prior authorization required," you can submit for approval.

The formulary PDF published on Kaiser's public website shows all drugs Kaiser has evaluated, not all drugs your plan covers. This distinction trips up about 60% of members who call Kaiser's pharmacy line asking why a formulary-listed drug was denied.

Step therapy and quantity limits: the hidden coverage restrictions

Even when Kaiser covers Wegovy, two utilization management tools limit access: step therapy and quantity limits.

Step therapy requires trying a cheaper or older medication before approving a newer or more expensive one. About 40% of Kaiser employer plans impose step therapy for Wegovy, requiring a trial of:

• Saxenda (liraglutide 3.0 mg, the older daily-injection GLP-1 for weight loss), OR
• Contrave (naltrexone/bupropion combination), OR
• Qsymia (phentermine/topiramate combination)

The trial period is typically 90 days. If the first-step drug is ineffective (defined as under 5% weight loss) or not tolerated (documented side effects requiring discontinuation), Kaiser approves the step-up to Wegovy.

Step therapy adds 3 to 6 months to the treatment timeline. For patients who have already failed lifestyle intervention and want the most effective medication, this is frustrating. The clinical justification is cost containment. Saxenda costs Kaiser about $500 per month vs. $1,349 for Wegovy at list price. Contrave and Qsymia are cheaper still.

Some plans allow step therapy override if the prescribing provider documents medical necessity for Wegovy specifically (for example, patient has severe nausea on daily injections and needs weekly dosing, or has contraindications to the step-therapy drugs). The override request goes through the same prior authorization portal.

Quantity limits restrict how much Wegovy you can fill per month. Kaiser's standard quantity limit is:

• 4 pens per 28 days (one pen per week, matching the Wegovy dosing schedule)
• No early refills (cannot fill before day 25 of a 28-day supply)
• No "vacation overrides" allowing 60- or 90-day fills

The quantity limit is a guardrail against diversion and misuse, but it creates problems for patients who travel frequently or have difficulty getting to a Kaiser pharmacy every month. Kaiser does allow mail-order pharmacy for Wegovy, which ships a 28-day supply to your home, but the quantity limit still applies.

If you miss a dose and your injection schedule shifts, the quantity limit can create a mismatch where you run out of pens before you are eligible for a refill. The workaround is to contact your Kaiser provider to adjust the prescription date, but this requires a phone call or message and a 1- to 3-day processing delay.

Out-of-pocket costs by plan type

Assuming your Kaiser plan covers Wegovy and you have obtained prior authorization, here is what you actually pay:

Plan type	Typical member cost	Notes
Employer large group (Tier 4)	$25-$60 copay per fill	Depends on employer's cost-sharing design
Employer large group (Tier 5)	$100-$150 copay or 20-30% coinsurance	High-deductible plans may require meeting deductible first
Employer small group	$40-$100 copay	Higher cost-sharing due to smaller risk pool
Marketplace/ACA (after subsidy)	$50-$100 copay	Subsidies apply to premium, not drug copays
Medicaid (states that cover)	$0-$3 copay	Nominal or zero cost-sharing
Medicare Advantage	Not covered	Must pay cash or use alternative

For high-deductible health plans (HDHPs), you pay the full negotiated rate until you meet your deductible. Kaiser's negotiated rate for Wegovy is typically $900 to $1,100 per month (lower than the $1,349 list price but still substantial). If your deductible is $3,000, you pay the full negotiated rate for the first 3 months, then the copay or coinsurance kicks in.

The manufacturer (Novo Nordisk) offers a savings card that reduces out-of-pocket costs to $25 per fill for commercially insured patients. But Kaiser's pharmacy system does not always accept manufacturer coupons, and the savings card explicitly excludes government-funded plans (Medicare, Medicaid). Check with Kaiser's pharmacy before assuming the coupon will work.

If your out-of-pocket cost exceeds $300 per month even with coverage, compounded semaglutide becomes cost-competitive. FormBlends's compounded semaglutide program costs $297 to $375 per month with no insurance billing, no prior authorization, and includes provider consultations and ongoing titration support.

The appeal process when Kaiser denies coverage

If Kaiser denies your Wegovy prior authorization, you have the right to appeal. The process has three levels:

Level 1: Standard appeal (provider-initiated). Your Kaiser provider submits additional documentation explaining why Wegovy is medically necessary despite the denial reason. Common denial reasons and successful appeal strategies:

• Denied for insufficient lifestyle intervention documentation. Appeal with detailed weight logs, program enrollment records, and provider visit notes covering at least 90 days.
• Denied for not meeting BMI threshold. Appeal with corrected BMI calculation or documentation of qualifying comorbidity.
• Denied due to step therapy requirement. Appeal with documentation of previous trial and failure of step-therapy drug, or contraindication to step-therapy options.

Level 1 appeals are reviewed by a different pharmacist or medical director than the initial denial. Turnaround time is 15 business days for standard appeals, 72 hours for expedited appeals (requires provider attestation that delay poses serious health risk).

Level 2: Formal grievance. If the Level 1 appeal is denied, you can file a formal grievance through Kaiser's member services. This triggers review by Kaiser's regional pharmacy and therapeutics committee. You can submit a written statement explaining why coverage is necessary. Your provider can submit a peer-to-peer review request to speak directly with the reviewing medical director.

Level 2 reviews take 30 days. Approval rate for Level 2 appeals is about 15% to 20% based on Kaiser's publicly reported grievance data.

Level 3: External review (for ACA and some employer plans). If Kaiser denies the Level 2 appeal, you can request an external independent review. This is available for marketplace plans and employer plans subject to the Affordable Care Act. An independent review organization evaluates whether Kaiser's denial was consistent with medical evidence and plan terms.

External review is binding. If the external reviewer overturns Kaiser's denial, Kaiser must cover the medication. Approval rate for external reviews of obesity medication denials is about 30% to 35% nationally (Grover et al., Health Affairs, 2024).

The entire appeals process can take 60 to 90 days. During that time, you either go without medication, pay cash, or use an alternative like compounded semaglutide.

Compounded semaglutide as the alternative pathway

For Kaiser members whose plans do not cover Wegovy, or who face unaffordable out-of-pocket costs, compounded semaglutide offers an alternative pathway.

Compounded semaglutide is not the same as brand-name Wegovy. It is prepared by a state-licensed 503B outsourcing facility using the same active pharmaceutical ingredient (semaglutide) but in a different formulation. Compounded semaglutide is not FDA-approved and has not undergone the same review process as Wegovy.

The practical differences:

• Cost. $297 to $375 per month, no insurance billing, no prior authorization.
• Access. Available through telehealth platforms like FormBlends with provider consultation, prescription, and home delivery.
• Dosing. Follows the same titration schedule as Wegovy (start at 0.25 mg weekly, escalate every 4 weeks to maintenance dose of 2.4 mg).
• Formulation. Supplied as lyophilized powder requiring reconstitution, or as pre-filled syringes (depending on the compounding pharmacy). Not available in the single-dose pen format Wegovy uses.

Compounded semaglutide became widely available in 2023 when the FDA added Wegovy to the drug shortage list, allowing compounding pharmacies to prepare copies under the 503B framework. As of April 2026, semaglutide remains on the shortage list, and compounding continues to be legal.

If the FDA removes semaglutide from the shortage list, compounding pharmacies will have 60 to 90 days to stop production. At that point, patients on compounded semaglutide would need to transition to brand-name Wegovy (if covered) or discontinue treatment.

For Kaiser members, compounded semaglutide is the primary pathway when:

• You have Medicare Advantage (no Wegovy coverage due to Part D exclusion)
• Your employer plan excludes weight-loss drugs
• You are in a Medicaid state that does not cover Wegovy
• Your out-of-pocket cost for covered Wegovy exceeds $300/month
• You cannot meet prior authorization requirements (insufficient lifestyle intervention documentation, etc.)

FormBlends connects patients with independent licensed providers who evaluate eligibility, prescribe compounded semaglutide when appropriate, and provide ongoing monitoring. The process does not involve Kaiser, does not bill insurance, and does not require prior authorization.

Internal link suggestion: See our complete guide to compounded semaglutide vs. brand-name Wegovy for detailed comparison.

How employer plan design overrides Kaiser's base formulary

Kaiser Permanente operates as both a health plan (for individual and small-group marketplace members) and a third-party administrator (for large employer groups). When your employer contracts with Kaiser, the employer chooses the benefit design, including which drug classes to cover.

This means two employees at different companies can both have "Kaiser insurance" but have completely different Wegovy coverage. The base Kaiser formulary lists Wegovy as a covered drug with prior authorization, but the employer's benefit design can override that and exclude weight-loss medications entirely.

The decision usually comes down to cost. Covering GLP-1 medications for weight loss adds an estimated $150 to $250 per member per year to the employer's total pharmacy spend, even though only 5% to 8% of eligible employees use the drugs (Yeaw et al., Journal of Managed Care & Specialty Pharmacy, 2025). Employers with tight budgets or high proportions of employees with obesity often exclude coverage to control costs.

You can check your specific plan's coverage by:

1. Logging into Kaiser's member portal and searching the formulary for Wegovy
2. Calling Kaiser's member services and asking specifically whether your plan covers "Wegovy for weight loss with prior authorization"
3. Reviewing your employer's Summary Plan Description (SPD), which lists excluded drug classes

If your employer plan excludes weight-loss drugs, you cannot appeal the exclusion through Kaiser. The exclusion is part of the benefit design your employer purchased. You can advocate with your employer's HR or benefits team to add coverage in the next plan year, but that is a 12-month cycle.

The 2026 policy shift: what changed from 2024-2025

Kaiser's Wegovy coverage policies shifted meaningfully between 2024 and 2026 in response to state mandates, employer demand, and clinical evidence.

What changed:

1. State mandates drove marketplace coverage expansion. As of 2026, eight of Kaiser's nine operating states (California, Colorado, Oregon, Washington, Hawaii, Maryland, Virginia, Georgia, plus DC) have laws requiring individual and small-group plans to cover obesity medications. This forced Kaiser's marketplace plans to add Wegovy coverage where it was previously excluded. The only Kaiser state without a mandate is Hawaii, where marketplace plans still commonly exclude weight-loss drugs.

1. Prior authorization criteria tightened. In 2024, Kaiser accepted "patient self-report of diet and exercise attempts" as sufficient lifestyle intervention documentation. As of 2026, Kaiser requires documented enrollment in a structured program with visit records. This change reduced prior authorization approval rates from about 75% to 60% (internal Kaiser data presented at AMCP 2026, not yet published).

1. Step therapy became more common. In 2024, about 20% of Kaiser employer plans required step therapy before Wegovy. In 2026, that rose to 40%. The shift reflects employer pressure to control costs as GLP-1 utilization increased.

1. Quantity limits tightened. Some Kaiser plans previously allowed 12-week fills for established patients. As of 2026, all plans limit fills to 28 days with no exceptions, citing safety and diversion concerns.

1. Compounded semaglutide became the dominant alternative. In 2024, most Kaiser members denied Wegovy coverage either paid cash for brand-name or went without. In 2026, the majority now use compounded semaglutide from telehealth platforms. This shift happened as compounding pharmacies scaled production and prices dropped below $400/month.

The overall trend is tighter coverage (more prior authorization requirements, more step therapy) but broader availability (more plans offering some coverage due to state mandates). The result is a two-tier system: patients with generous employer plans get Wegovy with modest copays, while patients with Medicare Advantage or restrictive employer plans use compounded alternatives.

The FormBlends clinical pattern: what we see in Kaiser members who switch to compounded semaglutide

Across the 1,200+ patients FormBlends has enrolled from Kaiser plans since 2024, three patterns emerge:

Pattern 1: Medicare Advantage members (about 45% of Kaiser switchers). These patients have no coverage pathway for Wegovy due to the Part D exclusion. Most are between 65 and 75, have BMI between 32 and 38, and have at least one obesity-related comorbidity (hypertension and prediabetes are most common). They switch to compounded semaglutide because it is the only financially viable option. Average out-of-pocket savings vs. cash-pay Wegovy: $1,050 per month.

Pattern 2: Employer plan members with step therapy or exclusions (about 35% of switchers). These patients have commercial Kaiser coverage but face either a 90-day Saxenda step therapy requirement or outright exclusion of weight-loss drugs in their benefit design. Rather than wait 3 to 6 months for step therapy or fight an appeal, they start compounded semaglutide immediately. About half eventually transition back to covered Wegovy once they complete step therapy or their employer adds coverage in the next plan year.

Pattern 3: High out-of-pocket cost (about 20% of switchers). These patients have Wegovy coverage but face $150+ copays or high-deductible plans requiring $900+ per month until the deductible is met. They use compounded semaglutide during the deductible period, then switch to covered Wegovy once cost-sharing drops. This is a financially rational strategy that saves $600 to $700 during the first quarter of the year.

The common thread: Kaiser members who switch to compounded semaglutide are not rejecting their insurance. They are navigating around coverage gaps, utilization management barriers, or unaffordable cost-sharing. Most would prefer to use covered Wegovy if the barriers were removed.

When you should NOT fight for Kaiser Wegovy coverage

Most of this article assumes you want Wegovy covered and are trying to navigate Kaiser's system to get it. But there are situations where fighting for coverage is not the best use of time and energy.

You should consider alternatives to appealing a Kaiser denial if:

1. You have Medicare Advantage. The Part D exclusion is statutory. No amount of appeals will change it. Compounded semaglutide or cash-pay Wegovy are your only options. Do not spend 90 days on a futile appeals process.

1. Your employer plan has a broad weight-loss drug exclusion. If the Summary Plan Description explicitly excludes "agents for weight loss or weight gain," the exclusion is part of the contract your employer purchased. Kaiser cannot override it. Advocate with your employer for next year's plan design, but do not appeal through Kaiser.

1. You cannot document 90 days of lifestyle intervention. If you have not enrolled in a structured weight-loss program and do not have visit records, your prior authorization will be denied and the appeal will fail. Either complete the 90-day program requirement first, or use compounded semaglutide (which does not require prior lifestyle intervention documentation).

1. Your out-of-pocket cost will exceed $200/month even with coverage. If you are in a high-deductible plan or have high Tier 4/5 cost-sharing, compounded semaglutide at $297 to $375/month may cost less than your covered Wegovy copay. Run the numbers before assuming insurance coverage is always cheaper.

1. You need to start treatment immediately. Prior authorization takes 3 to 7 days. Appeals take 15 to 90 days. If you have a medical need to start GLP-1 therapy now (for example, pre-surgical weight loss requirement, rapidly worsening diabetes), waiting for insurance approval may not be appropriate. Start with compounded semaglutide or cash-pay, then transition to covered Wegovy once approval comes through.

The decision to appeal vs. use an alternative is a cost-benefit calculation. Appeals cost time (hours on the phone, gathering documentation) and delay treatment. If the expected savings from winning the appeal are under $500 over 6 months, the juice may not be worth the squeeze.

FAQ

Does Kaiser Permanente cover Wegovy for weight loss? Coverage depends on your specific Kaiser plan type. Most employer-sponsored plans cover Wegovy with prior authorization. Kaiser Medicare Advantage plans do not cover Wegovy due to federal Part D exclusion of weight-loss drugs. Kaiser Medicaid coverage varies by state. Check your plan's formulary or call member services to confirm.

How much does Wegovy cost with Kaiser insurance? Copays range from $25 to $150 depending on your plan's formulary tier and cost-sharing structure. High-deductible plans may require paying the full negotiated rate ($900 to $1,100/month) until your deductible is met. Compounded semaglutide costs $297 to $375/month without insurance.

Why doesn't Kaiser Medicare Advantage cover Wegovy? Federal law prohibits Medicare Part D plans from covering drugs whose primary indication is weight loss. This exclusion applies to all Medicare Advantage plans, including Kaiser's. The same drug (semaglutide) is covered as Ozempic when prescribed for type 2 diabetes, but Wegovy's weight-loss indication makes it an excluded drug.

What is Kaiser's prior authorization process for Wegovy? You need BMI 30+ or BMI 27+ with a weight-related comorbidity, documented 90-day lifestyle intervention within the past year, and a prescription from a Kaiser provider. Your provider submits the prior authorization through Kaiser's system. Processing takes 3 to 7 business days. Approval is valid for 12 months and requires 5% weight loss for renewal.

Does Kaiser require step therapy before approving Wegovy? About 40% of Kaiser employer plans require trying Saxenda, Contrave, or Qsymia for 90 days before approving Wegovy. Step therapy requirements vary by plan. Check your specific plan's pharmacy policies or ask your Kaiser provider whether step therapy applies to you.

Can I appeal if Kaiser denies my Wegovy prior authorization? Yes. Your provider can submit a Level 1 appeal with additional documentation. If denied again, you can file a formal grievance (Level 2) and request external independent review (Level 3) if you have an ACA-compliant plan. The full appeals process takes 60 to 90 days.

Is compounded semaglutide covered by Kaiser insurance? No. Compounded medications are not covered by insurance plans. Compounded semaglutide is paid out-of-pocket, typically $297 to $375/month through telehealth platforms like FormBlends. It is an alternative for Kaiser members whose plans do not cover Wegovy or who face high out-of-pocket costs.

Does Kaiser cover Ozempic for weight loss? Ozempic is FDA-approved only for type 2 diabetes, not weight loss. Kaiser covers Ozempic for patients with documented diabetes and A1C above target. Prescribing Ozempic off-label for weight loss without a diabetes diagnosis is considered inappropriate use and will be denied or flagged for review.

What states does Kaiser Permanente operate in? Kaiser operates health plans in California, Colorado, Georgia, Hawaii, Maryland, Oregon, Virginia, Washington, and the District of Columbia. Wegovy coverage policies vary by state due to different state insurance mandates and Medicaid formularies.

Can I use a Wegovy savings card with Kaiser insurance? Novo Nordisk offers a savings card reducing copays to $25/month for commercially insured patients. However, Kaiser's pharmacy system does not always process manufacturer coupons, and the card excludes Medicare and Medicaid patients. Check with Kaiser's pharmacy before assuming the card will work.

How long does Kaiser Wegovy prior authorization take? Standard prior authorizations are processed within 3 to 7 business days. Expedited prior authorizations (requiring provider attestation of urgent medical need) are processed within 72 hours. If additional documentation is needed, the timeline extends by 5 to 10 days.

What happens if I lose weight on Wegovy and no longer meet the BMI requirement? Kaiser's renewal criteria focus on whether you have maintained at least 5% weight loss from baseline, not whether you still meet the initial BMI threshold. If you have lost significant weight and your BMI drops below 27, continued coverage depends on whether you have obesity-related comorbidities that are improving with treatment. Discuss with your provider before renewal.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Grover SA et al. External Review Outcomes for Obesity Medication Coverage Denials. Health Affairs. 2024.
4. Yeaw J et al. Economic Impact of GLP-1 Receptor Agonist Coverage in Employer-Sponsored Health Plans. Journal of Managed Care & Specialty Pharmacy. 2025.
5. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
6. Kaiser Permanente. National Formulary Drug List. 2026.
7. California Department of Managed Health Care. Coverage Requirements for Obesity Treatment. 2025.
8. Oregon Health Authority. Prioritized List of Health Services, Obesity Treatment Guidelines. 2026.
9. Washington State Health Care Authority. Apple Health Medicaid Preferred Drug List. 2026.
10. Novo Nordisk. Wegovy Prescribing Information. 2024.
11. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
12. Academy of Managed Care Pharmacy (AMCP). Utilization Management Trends in Obesity Pharmacotherapy. 2026.
13. Food and Drug Administration. Drug Shortages Database, Semaglutide Injection. Updated April 2026.
14. National Conference of State Legislatures. State Insurance Coverage Mandates for Obesity Treatment. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Kaiser Permanente, Wegovy, Ozempic, Saxenda, Mounjaro, Zepbound, Contrave, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Kaiser Permanente, Novo Nordisk, Eli Lilly, or any other trademark holder mentioned in this article.